Discussion
From a cohort of 28.868 patients with different types of solid tumors, a
high frequency of IDH1/IDH2 mutations were observed not only in
biliary tract cancer, but also liver cancer, lung cancer, colorectal
cancer and others. The reprogramming of cellular metabolism is a
fundamental characteristic of cancer, and IDH1/2 mutations
represent key therapeutic targets in this arena. Somatic IDH1/2mutations are found in multiple solid tumors, and mounting evidence
indicates that they contribute to premalignant disorders as well as
early and late cancers. And then, another interesting point, we found
that TMB was higher in other gastrointestinal tumors. However, in
biliary tract cancer, IDH mutation accompanied by low TMB indicates that
IDH would be a driver gene in biliary tract cancer. With the continuous
emergence of IDH inhibitors, a considerable number of patients with
solid tumors carrying IDH1/2 gene mutations may be more likely to
benefit from IDH inhibitors, which is worth further expectation and
exploration in clinical studies.